Eli Lilly Digital Transformation Strategy Analysis Report 2025: Accelerators, Innovation Programs, Technology Initiatives, ICT, Partnerships, Investments & Acquisitions, Network Map
Dublin, April 09, 2026 (GLOBE NEWSWIRE) -- The "Enterprise Tech Ecosystem Series: Eli Lilly - 2025" company profile has been added to ResearchAndMarkets.com's offering.
The report provides insights into the company's tech activities, including its digital transformation strategies, its innovation programs, its technology initiatives, and its investments.
Elli Lilly and Company (Eli Lilly) is an American pharmaceutical company engaged in the discovery, development, manufacturing, and marketing of pharmaceutical products.
The company manufactures and distributes products for cardiometabolic health, oncology, immunology, and neuroscience. Eli Lilly has drug manufacturing facilities in the US, Asia, and Europe, and it sells its products in over 95 countries.
The company holds patents for hundreds of branded drugs, including Jardiance, Mounjaro/ Zepbound, Trulicity, Cyramza, Jaypirca, Retevmo, Verzenio, Olumiant, Ebglyss, Taltz, and Omvoh, among others. The company has only one business segment: human pharmaceutical products.
The report provides information and insights into Eli Lilly's tech activities, including:
Reasons to Buy
Key Topics Covered:
Companies Featured
For more information about this company profile visit https://www.researchandmarkets.com/r/90o3y4
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.